Australia's Prescient Therapeutics rises on getting U.S. patent

Prescient Therapeutics

05/07/2022 02:04

** Shares of clinical-stage oncology co Prescient
Therapeutics  PTX.AX  rise as much as 9.1% to A$0.180, their
highest since June 17
    ** Co says it has been granted U.S. patent in the OmniCAR
portfolio, which is a universal immune receptor platform that
creates modular cell therapies  urn:newsml:reuters.com:*:nASX33nTFS
    ** Says the patent provides protection in the U.S.
healthcare market till at least 2039
    ** As of last close, stock down 28.3% this year

 (Reporting by Himanshi Akhand in Bengaluru)
 ((Himanshi.Akhand@thomsonreuters.com;))